

Ali Bazarbachi

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5827788/publications.pdf](https://exaly.com/author-pdf/5827788/publications.pdf)

Version: 2024-02-01

337
papers

10,650
citations

38552

50
h-index

49007

88
g-index

392
all docs

392
docs citations

392
times ranked

13404
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2024, 59, 217-223.	2.4	3
2	Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1 mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>American Journal of Hematology</i> , 2024, 99, 360-369.	4.3	1
3	Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. <i>Blood Cancer Journal</i> , 2024, 14, .	6.3	5
4	In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2024, 59, 526-533.	2.4	0
5	Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study. <i>Clinical Cancer Research</i> , 2024, 30, 1778-1787.	7.2	0
6	Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2024, 99, 1290-1299.	4.3	0
7	Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients. <i>Blood Cancer Journal</i> , 2024, 14, .	6.3	0
8	Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience. <i>Journal of Clinical Medicine</i> , 2024, 13, 2718.	2.5	0
9	Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. <i>Blood Cancer Journal</i> , 2024, 14, .	6.3	0
10	Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2023, 58, 61-67.	2.4	2
11	Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. <i>Bone Marrow Transplantation</i> , 2023, 58, 534-543.	2.4	7
12	Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. <i>Bone Marrow Transplantation</i> , 2023, 58, 667-672.	2.4	2
13	Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2023, 58, 710-716.	2.4	4
14	Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2023, 58, 784-790.	2.4	4
15	Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. <i>Blood Cancer Journal</i> , 2023, 13, .	6.3	10
16	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2023, 58, 749-754.	2.4	25
17	Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF- κ B activation and survival. <i>Blood Cancer Journal</i> , 2023, 13, .	6.3	7
18	Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party. <i>Clinical Cancer Research</i> , 2023, 29, 4441-4448.	7.2	3

#	ARTICLE	IF	CITATIONS
19	Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2083-2097.	2.6	5
20	Prevention of acute graft-versus-host disease in adult T-cell leukemia lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2022, 115, 435-439.	1.6	4
21	Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 147-148.	2.4	4
22	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	2.6	14
23	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	2.4	22
24	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 1068-1080.	2.9	7
25	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	7.2	15
26	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	2.4	5
27	Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!. <i>Cancers</i> , 2022, 14, 1490.	3.8	10
28	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. <i>Blood Cancer Journal</i> , 2022, 12, 47.	6.3	23
29	Pembrolizumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after autologous transplant and in transplant-naïve patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	5
30	Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran. <i>Viruses</i> , 2022, 14, 664.	3.4	5
31	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 934-941.	2.4	1
32	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	7.5	7
33	The efficacy and safety of BV-ICE salvage therapy for relapsed/refractory Hodgkin lymphoma. A single centre. <i>Current Research in Translational Medicine</i> , 2022, 70, 103339.	2.0	0
34	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	2.4	7
35	Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Hematology International</i> , 2022, 4, 30-34.	1.9	2
36	EVIDÊNCIAS EMPÍRICAS DE MUDANÇAS ENCAIXADAS NO PB A PARTIR DOS TRABALHOS DE DUARTE (1992,1993) Tj ETQq0 0 0 rgBT Linguísticos E Literários, 2022, , 271-298.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. <i>Cancer</i> , 2022, 128, 2922-2931.	4.1	22
38	Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. <i>International Journal of Hematology</i> , 2022, 116, 330-340.	1.6	29
39	Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1657-1663.	2.4	6
40	Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). <i>Bone Marrow Transplantation</i> , 2022, 57, 1803-1809.	2.4	9
41	Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1774-1780.	2.4	8
42	Clinical characteristics and outcomes of bone marrow transplantation patients presenting to the ED of a tertiary care center. <i>American Journal of Emergency Medicine</i> , 2021, 46, 295-302.	1.7	1
43	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	2.4	39
44	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	33
45	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	2.4	10
46	Vitamins and minerals intake adequacy in hematopoietic stem cell transplant: results of a randomized controlled trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1106-1115.	2.4	7
47	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021, 10, 23-33.	2.9	8
48	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	2.4	12
49	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 209-218.	4.1	30
50	Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. <i>Clinical Hematology International</i> , 2021, 3, 21.	1.9	11
51	Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 21-32.	1.7	10
52	Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells. <i>Haematologica</i> , 2021, 106, 1443-1456.	3.5	12
53	Diagnostic performance of F-18 FDG PET/CT in the detection of bone marrow involvement in paediatric hodgkin lymphoma: A meta-analysis. <i>Leukemia Research</i> , 2021, 102, 106525.	1.1	3
54	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	4.6	27

#	ARTICLE	IF	CITATIONS
55	Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective. <i>British Journal of Haematology</i> , 2021, 195, 495-506.	2.7	5
56	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	13
57	Comprehensive Review of AL amyloidosis: some practical recommendations. <i>Blood Cancer Journal</i> , 2021, 11, 97.	6.3	46
58	The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. <i>Current Research in Translational Medicine</i> , 2021, 69, 103285.	2.0	7
59	Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 711-719.	0.4	2
60	Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 2518-2532.	2.4	9
61	A Pin1/PML/P53 axis activated by retinoic acid in NPM1c acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 3090-3099.	3.5	13
62	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. <i>Leukemia Research</i> , 2021, 105, 106568.	1.1	3
63	Implemented Interventions at the Naef K. Basile Cancer Institute to Protect Patients and Medical Personnel From COVID Infections: Effectiveness and Patient Satisfaction. <i>Frontiers in Oncology</i> , 2021, 11, 685107.	2.9	1
64	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	14.2	43
65	Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature. <i>Current Research in Translational Medicine</i> , 2021, 69, 103296.	2.0	5
66	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.4	1
67	Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Soci� Francophone de Greffe de Moelle et de Therapie Cellulaire. <i>Bone Marrow Transplantation</i> , 2021, 56, 2849-2856.	2.4	2
68	Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2626-2627.	2.4	2
69	First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 564-566.	0.4	1
70	COVID-19 vaccination immune response in patients with solid organ and haematologic malignancies: call for active monitoring. <i>Ecancermedicalscience</i> , 2021, 15, 1284.	1.1	1
71	Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions. <i>Cancers</i> , 2021, 13, 4698.	3.8	4
72	Bacterial bloodstream infections and patterns of resistance in patients with haematological malignancies at a tertiary centre in Lebanon over 10 years. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 27, 228-235.	2.5	12

#	ARTICLE	IF	CITATIONS
73	In vivo antagonistic role of the Human T-Cell Leukemia Virus Type 1 regulatory proteins Tax and HBZ. PLoS Pathogens, 2021, 17, e1009219.	4.1	14
74	Strategic priorities for hematopoietic stem cell transplantation in the EMRO region. Hematology/Oncology and Stem Cell Therapy, 2021, , .	0.9	3
75	The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience. Journal of Fungi (Basel,) Tj ETQq1 1 0.784334rgBT /Overlock		
76	Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities. Current Oncology Reports, 2021, 23, 141.	4.1	15
77	Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines, 2021, 9, 1704.	3.3	6
78	The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation. Frontiers in Oncology, 2021, 11, 793274.	2.9	5
79	Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 175-177.	0.9	1
80	Validation of a <i>Drosophila</i> model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening. Haematologica, 2020, 105, 387-397.	3.5	8
81	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	2.4	73
82	Corrigendum to "Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis" [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]. Biology of Blood and Marrow Transplantation, 2020, 26, 209-212.	2.0	3
83	Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 979-981.	2.4	2
84	Prophylaxie antivirale pour le CMV, l'HSV/VZV et le VHB aprs allogreffe de cellules souches hmatopoïtiques chez l'adulte: recommandations de la Socié francophone de greffe de mlle et de thrapie cellulaire (SFGM-TC). Bulletin Du Cancer, 2020, 107, S1-S6.		8
85	A BSDE approach to a class of dependent risk model of mean-variance insurers with stochastic volatility and no-short selling. Journal of Computational and Applied Mathematics, 2020, 366, 112413.	2.0	18
86	Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 371-376.e1.	0.4	2
87	FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia, 2020, 34, 682-696.	7.5	150
88	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biology of Blood and Marrow Transplantation, 2020, 26, 936-942.	2.0	16
89	Non-irradiated GCSF stimulated leukocyte transfusion for necrotizing fasciitis after allogeneic stem cell transplant: a case report and review of the literature. Bone Marrow Transplantation, 2020, 55, 1000-1003.	2.4	0
90	Diagnosing Lymphoproliferative Disorders Using Core Needle Biopsy Versus Surgical Excisional Biopsy: Three-Year Experience of a Reference Center in Lebanon. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e455-e460.	0.4	8

#	ARTICLE	IF	CITATIONS
91	D'Épistage des bactéries multirésistantes (BMR) et hautement résistantes émergentes (BHRe) aux antibiotiques en allogreffe de cellules souches hématopoïétiques: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin Du Cancer, 2020, 107, S7-S11.	0.8	0
92	Return-to-work support in cancer patients: Which methodology?. Bulletin Du Cancer, 2020, 107, 200-208.	0.8	5
93	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	7.2	45
94	Maliwawa figures a previously undescribed Arnhem Land rock art style. Australian Archaeology, 2020, 86, 208-225.	0.9	21
95	Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2020, 10, 596134.	2.9	13
96	Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Advances in Therapy, 2020, 37, 4033-4042.	3.0	21
97	Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT. Current Research in Translational Medicine, 2020, 68, 145-148.	2.0	0
98	Bisoprolol, a β_1 antagonist, protects myocardial cells from ischemia-reperfusion injury via PI3K/AKT/GSK3 β pathway. Fundamental and Clinical Pharmacology, 2020, 34, 708-720.	2.1	10
99	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 617-623.	0.4	27
100	Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. Frontiers in Microbiology, 2020, 11, 1207.	3.6	35
101	Novel Treatments of Adult T Cell Leukemia Lymphoma. Frontiers in Microbiology, 2020, 11, 1062.	3.6	33
102	Arsenic trioxide (As ₂ O ₃) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology, 2020, 17, 5.	2.2	21
103	Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Bone Marrow Transplantation, 2020, 55, 1485-1490.	2.4	1
104	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 296-304.	0.4	6
105	Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 1732-1735.	1.4	5
106	The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study. Current Research in Translational Medicine, 2020, 68, 51-58.	2.0	2
107	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplantation, 2020, 55, 1525-1532.	2.4	18
108	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	102

#	ARTICLE	IF	CITATIONS
109	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	115
110	Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Protocol for the Treatment of High-Grade B Cell Lymphoma. <i>Blood</i> , 2020, 136, 49-50.	1.4	2
111	Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. <i>Clinical Hematology International</i> , 2020, 2, 92.	1.9	2
112	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	4.3	10
113	A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology. <i>Genes</i> , 2019, 10, 614.	2.4	22
114	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. <i>Nature Communications</i> , 2019, 10, 2891.	13.2	38
115	Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071988266.	2.5	24
116	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.5	52
117	Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis. <i>Medical Mycology Case Reports</i> , 2019, 23, 68-71.	1.3	3
118	Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature. <i>Molecular Biology Reports</i> , 2019, 46, 2003-2011.	2.4	2
119	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	15.4	170
120	Recent advances in quorum quenching of plant pathogenic bacteria. , 2019, , 233-245.		4
121	Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 506-508.	0.4	36
122	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1695-1700.	2.0	14
123	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	90
124	Complete sequence of human T cell leukemia virus type 1 in ATLL patients from Northeast Iran, Mashhad revealed a prematurely terminated protease and an elongated pX open reading frame III. <i>Infection, Genetics and Evolution</i> , 2019, 73, 460-469.	2.3	9
125	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	24
126	Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 2818-2828.	4.1	14

#	ARTICLE	IF	CITATIONS
127	A highly selective and sensitive red-emitting fluorescent probe for visualization of endogenous peroxynitrite in living cells and zebrafish. <i>Analyst</i> , 2019, 144, 3442-3449.	3.5	20
128	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	3.5	47
129	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.4	33
130	Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience. <i>Current Research in Translational Medicine</i> , 2019, 67, 16-19.	2.0	10
131	PAX5, NOTCH3, CFBF, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1124-1128.	2.4	3
132	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	87
133	Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBT) Group. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 127-132.	0.9	20
134	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	4.1	15
135	The impact of counseling on nutritional status among hematopoietic stem cell recipients: results of a randomized controlled trial. <i>Bone Marrow Transplantation</i> , 2019, 54, 752-756.	2.4	8
136	Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 620-624.	2.4	14
137	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology International</i> , 2019, 1, 58.	1.9	50
138	Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Unrelated Cord Blood in Patients with T-Cell Non-Hodgkin Lymphoma : A Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGMC-TC). <i>Blood</i> , 2019, 134, 4596-4596.	1.4	0
139	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	2.7	24
140	Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 368-374.	0.4	3
141	Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner. <i>Oncogene</i> , 2018, 37, 2806-2816.	5.9	18
142	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	2.4	36
143	Acute promyelocytic leukemia with increased bone marrow reticulin fibrosis: Description of three cases and review of the literature. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 99-104.	0.9	8
144	The Effect of Differential Incentives on Attrition Bias. <i>Field Methods</i> , 2018, 30, 56-69.	0.8	9

#	ARTICLE	IF	CITATIONS
145	P3Ȼ: ASSOCIATION OF FUNCTIONAL DENTITION WITH THE RISK OF COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1343.	0.7	0
146	Early returning longâdistance migrant males do pay a survival cost. Ecology and Evolution, 2018, 8, 11434-11449.	1.9	37
147	Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e441-e444.	0.4	20
148	Mouse Models That Enhanced Our Understanding of Adult T Cell Leukemia. Frontiers in Microbiology, 2018, 9, 558.	3.6	7
149	Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. Frontiers in Microbiology, 2018, 9, 925.	3.6	10
150	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncology, 2018, 4, 1245.	7.3	107
151	The HTLV-1 oncoprotein Tax is modified by the ubiquitin related modifier 1 (Urm1). Retrovirology, 2018, 15, 33.	2.2	11
152	Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series. Infection, 2018, 46, 811-821.	5.2	15
153	Polyimide film with low thermal expansion and high transparency by self-enhancement of polyimide/SiC nanofibers net. RSC Advances, 2018, 8, 19034-19040.	3.7	27
154	HTLV-1-associated adult T-cell leukemia-lymphoma. Hematologie, 2018, 24, 104-110.	0.0	0
155	Role of 2677GâTâA Genetic Polymorphism in the ABCB1 Drug Transporter in the Interaction between Voriconazole and Cyclosporine and Cyclosporine Related Nephrotoxicity After Allogeneic Stem Cell Transplantation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-6.	0.0	0
156	Hyperfractionated radiation therapy in Burkitt's lymphoma: a reconsideration aspect. Hematological Oncology, 2017, 35, 856-860.	1.8	3
157	Parameters affecting forced convection enhancement in ferrofluid cooling systems. Applied Thermal Engineering, 2017, 123, 156-166.	6.1	21
158	Charging Architectures Integrated with Distributed Energy Resources for Sustainable Mobility. Energy Procedia, 2017, 105, 2317-2322.	1.8	7
159	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fmsâlike tyrosine kinase 3âmutated acute myeloid leukemia. Cancer, 2017, 123, 2867-2874.	4.1	104
160	Mindfulness practice reduces cortisol blunting during chemotherapy: A randomized controlled study of colorectal cancer patients. Cancer, 2017, 123, 3088-3096.	4.1	24
161	Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. Leukemia and Lymphoma, 2017, 58, 2745-2747.	1.4	3
162	Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma. Methods in Molecular Biology, 2017, 1582, 197-216.	0.0	23

#	ARTICLE	IF	CITATIONS
163	Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Virology</i> , 2017, 95, 36-41.	3.4	12
164	CDK9 inhibition for ATL therapy. <i>Blood</i> , 2017, 130, 1074-1075.	1.4	4
165	Trends in hematopoietic stem cell transplant activity in Lebanon. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 315-320.	0.9	8
166	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	139
167	microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis. <i>Scientific Reports</i> , 2017, 7, 16829.	3.4	24
168	Non-model model organisms. <i>BMC Biology</i> , 2017, 15, 55.	3.9	171
169	Reducing the global burden of HTLV-1 infection: An agenda for research and action. <i>Antiviral Research</i> , 2017, 137, 41-48.	4.2	120
170	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.4	5
171	Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 179-185.	0.4	21
172	Stratégies préventives et thérapeutiques de la rechute après allogreffe de cellules souches hématopoïétiques: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). <i>Bulletin Du Cancer</i> , 2017, 104, S84-S98.	0.8	10
173	Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon- β . <i>Blood Advances</i> , 2017, 1, 748-752.	5.4	24
174	No significant HTLV seroprevalence in German people who inject drugs. <i>PLoS ONE</i> , 2017, 12, e0183496.	2.5	2
175	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	3.5	12
176	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2016, 17, e1.	10.8	0
177	Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 304-310.	0.4	9
178	Tax fingerprint in adult T-cell leukemia. <i>Blood</i> , 2016, 127, 1737-1738.	1.4	6
179	Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. <i>European Journal of Human Genetics</i> , 2016, 24, 1268-1273.	2.9	38
180	Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML. <i>Blood</i> , 2016, 128, 5872-5872.	1.4	1

#	ARTICLE	IF	CITATIONS
181	MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. <i>Oncotarget</i> , 2016, 7, 82338-82353.	2.1	22
182	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). <i>Blood</i> , 2016, 128, 5824-5824.	1.4	0
183	Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBT). <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 167-175.	0.9	15
184	ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. <i>Blood</i> , 2015, 125, 474-482.	1.4	61
185	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <i>Blood</i> , 2015, 125, 3447-3454.	1.4	105
186	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. <i>Oncotarget</i> , 2015, 6, 2549-2561.	2.1	98
187	Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv032.	0.9	11
188	Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Leukemia Research</i> , 2015, 39, 933-937.	1.1	24
189	Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 298-302.	0.4	89
190	A Transgenic <i>Drosophila melanogaster</i> Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation <i>In Vivo</i> . <i>Journal of Virology</i> , 2015, 89, 8092-8095.	3.5	25
191	KIR genotype distribution among Lebanese patients with Hodgkin's lymphoma. <i>Meta Gene</i> , 2015, 4, 57-63.	0.6	4
192	Adult T-Cell Leukaemia/Lymphoma (ATL)., 2015, , 183-197.		0
193	Transplantation in adult T-cell leukemia/lymphoma. , 2015, , 209-216.		0
194	EAPB0503, a novel imidazoquinoline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. <i>Anti-Cancer Drugs</i> , 2014, 25, 624-632.	1.4	16
195	The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" micro-environment in patients with adult T-cell leukemia lymphoma. <i>Retrovirology</i> , 2014, 11, .	2.2	1
196	Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26-30 June 2013, Montreal, Canada. <i>Retrovirology</i> , 2014, 11, 19.	2.2	7
197	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	97
198	Focus on Treatment of HTLV-I-Associated Adult T-Cell Leukemia/Lymphoma. <i>Hematologie</i> , 2014, 20, 97-110.	0.0	1

#	ARTICLE	IF	CITATIONS
199	Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma. <i>Blood</i> , 2014, 124, 2072-2080.	1.4	33
200	Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia. <i>Blood</i> , 2014, 124, 5884-5884.	1.4	7
201	miRNA as Potential Biomarkers of Breast Cancer in the Lebanese Population and in Young Women: A Pilot Study. <i>PLoS ONE</i> , 2014, 9, e107566.	2.5	29
202	G-CSF Plus Preemptive Plerixafor Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma: Effectiveness, Safety and Cost Analysis. <i>Blood</i> , 2014, 124, 5823-5823.	1.4	0
203	Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran. <i>Acta Neurologica Belgica</i> , 2013, 113, 427-433.	1.1	21
204	A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses. <i>Pathology and Oncology Research</i> , 2013, 19, 715-722.	1.9	13
205	Therapeutic Options for Adult T-Cell Leukemia/Lymphoma. <i>Current Oncology Reports</i> , 2013, 15, 457-464.	4.1	38
206	The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. <i>Retrovirology</i> , 2013, 10, 91.	2.2	38
207	Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2013, 6, 14-19.	0.9	23
208	Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 747-748, 40-47.	1.0	25
209	Efficacy of Adoptive Immunotherapy with Donor Lymphocyte Infusion in Relapsed Lymphoid Malignancies. <i>Immunotherapy</i> , 2013, 5, 457-466.	2.0	42
210	Human T Cell Leukemia Virus Type 2 Tax-Mediated NF- κ B Activation Involves a Mechanism Independent of Tax Conjugation to Ubiquitin and SUMO. <i>Journal of Virology</i> , 2013, 87, 1123-1136.	3.5	42
211	Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries. <i>OMICS A Journal of Integrative Biology</i> , 2013, 17, 353-367.	2.0	24
212	Combination of Arsenic and Interferon- γ Inhibits Expression of KSHV Latent Transcripts and Synergistically Improves Survival of Mice with Primary Effusion Lymphomas. <i>PLoS ONE</i> , 2013, 8, e79474.	2.5	5
213	Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF- κ B activation. <i>Frontiers in Microbiology</i> , 2013, 4, 231.	3.6	27
214	Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-8.	1.5	17
215	Hematopoietic Stem Cell Allografting for Chronic Lymphocytic Leukemia: A Focus on Reduced-Intensity Conditioning Regimens. <i>Cancer Control</i> , 2012, 19, 68-75.	1.9	28
216	Animal models on HTLV-1 and related viruses: what did we learn?. <i>Frontiers in Microbiology</i> , 2012, 3, 333.	3.6	37

#	ARTICLE	IF	CITATIONS
217	Low nuclear body formation and tax SUMOylation do not prevent NF-kappaB promoter activation. <i>Retrovirology</i> , 2012, 9, 77.	2.2	21
218	The Multifaceted Oncoprotein Tax. <i>Advances in Cancer Research</i> , 2012, 113, 85-120.	6.3	44
219	Acellular Bone Marrow Extracts Significantly Enhance Engraftment Levels of Human Hematopoietic Stem Cells in Mouse Xeno-Transplantation Models. <i>PLoS ONE</i> , 2012, 7, e40140.	2.5	4
220	Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 877-884.	1.6	12
221	Paraneoplastic Syndromes in Primary CNS Lymphoma. , 2012, , 67-73.		0
222	Severe burn injury induces a characteristic activation of extracellular signal-regulated kinase 1/2 in spinal dorsal horn neurons. <i>European Journal of Pain</i> , 2011, 15, 683-690.	2.9	9
223	Trends of Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region, 1984-2007. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1352-1361.	2.0	21
224	High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. <i>Journal of Clinical Virology</i> , 2011, 52, 172-176.	3.4	154
225	The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?. <i>Cancer Discovery</i> , 2011, 1, 117-127.	14.2	45
226	Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. <i>Blood</i> , 2011, 117, 190-199.	1.4	60
227	How I treat adult T-cell leukemia/lymphoma. <i>Blood</i> , 2011, 118, 1736-1745.	1.4	144
228	Monique Desroches et al., dir. 2011. Territoires musicaux mis en sc�ne. Montr�al: Les Presses de l'Universit� de Montr�al. 424 p. ISBN 978-2-7606-2246-3. Intersections: <i>Canadian Journal of Music</i> , 2011, 31, 139.		0
229	Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 133-134.	1.8	24
230	Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. <i>International Journal of Cancer</i> , 2011, 129, 1006-1017.	5.4	21
231	Gallotannin inhibits NF�B signaling and growth of human colon cancer xenografts. <i>Cancer Biology and Therapy</i> , 2011, 12, 59-68.	3.7	58
232	Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 1-9.	0.9	2
233	JAK2 V617F Gene Mutation in the Laboratory Work-Up of Myeloproliferative Disorders: Experience of a Major Referral Center in Lebanon. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 263-265.	0.8	20
234	Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects?. <i>Viruses</i> , 2011, 3, 750-769.	3.4	36

#	ARTICLE	IF	CITATIONS
235	A Comprehensive Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viral Infections. <i>Blood</i> , 2011, 118, 5220-5220.	1.4	0
236	Synthesis of polyvinylpyrrolidone and its nanosilver-based polymer composites in supercritical carbon dioxide. <i>Polymer Science - Series B</i> , 2010, 52, 165-173.	0.8	12
237	Myasthenia gravis developing in a patient with CNS lymphoma. <i>International Journal of Hematology</i> , 2010, 91, 522-524.	1.6	10
238	Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. <i>Journal of Neuroimmunology</i> , 2010, 227, 185-189.	2.4	318
239	Modification and Implementation of NCCN Guidelines on Lymphomas in the Middle East and North Africa Region. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-29-S-35.	10.4	3
240	UKPDS Risk Engine, Decode and Diabetes PHD Models for the Estimation of Cardiovascular Risk in Patients with Diabetes. <i>Current Diabetes Reviews</i> , 2010, 6, 1-8.	1.3	15
241	Meta-Analysis on the Use of Zidovudine and Interferon-Alpha in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes. <i>Journal of Clinical Oncology</i> , 2010, 28, 4177-4183.	15.4	325
242	Reply to K. Ishitsuka et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e766-e766.	15.4	0
243	Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 2785-2792.	8.8	85
244	JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCR. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 13-15.	0.8	4
245	Emerging Role of CD20 Blockade in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1347-1354.	2.0	18
246	Distribution of Killer Cell Immunoglobulin-like Receptor (KIR) Genotypes in Patients with Familial Mediterranean Fever. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 91-95.	0.8	6
247	Distribution of Cytokine Gene Polymorphisms in the General Lebanese Population: The First Report. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 459-463.	0.8	0
248	Absence of JAK2 V617F mutation in thalassemia intermedia patients. <i>Molecular Biology Reports</i> , 2009, 36, 1555-1557.	2.4	10
249	Interaction Between Polyamine and Nitric Oxide Signaling in Adaptive Responses to Drought in Cucumber. <i>Journal of Plant Growth Regulation</i> , 2009, 28, 177-186.	5.0	107
250	Adult T cell leukemia-lymphoma with testicular involvement. <i>Annals of Hematology</i> , 2009, 88, 591-592.	1.8	0
251	Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. <i>Transfusion</i> , 2009, 49, 1859-1864.	1.8	14
252	Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 565-566.	1.1	5

#	ARTICLE	IF	CITATIONS
253	Scintigraphic Imaging of Pericarditis. <i>Clinical Cardiology</i> , 2009, 32, E89-E89.	1.9	1
254	Differences in response to fetal hemoglobin induction therapy in β^2 -thalassemia and sickle cell disease. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 58-62.	1.5	19
255	Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). <i>Blood</i> , 2009, 113, 6528-6532.	1.4	176
256	Declining tendency of human T-cell leukaemia virus type I carrier rates among blood donors in Mashhad, Iran. <i>Pathology</i> , 2009, 41, 498-499.	0.7	25
257	Long-term outcome of adult acute lymphoblastic leukemia in Lebanon. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2009, 2, 333-339.	0.9	8
258	First Line Antiviral Therapy Significantly Improves Survival of Patients with Acute, Chronic and Smoldering ATL: a Worldwide Meta-Analysis.. <i>Blood</i> , 2009, 114, 108-108.	1.4	1
259	Pediatric Sibling Donor Complications of Hematopoietic Stem Cell Collection: EBMT Pediatric Diseases Working Party Study.. <i>Blood</i> , 2009, 114, 806-806.	1.4	4
260	Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?. <i>BMJ Case Reports</i> , 2009, 2009, bcr0120091449-bcr0120091449.	0.5	0
261	Natural Killer Cell Immunoglobulin-like Receptors (KIR) Genotypes in two Arab Populations: Will KIR become a genetic landmark between nations?. <i>Molecular Biology Reports</i> , 2008, 35, 225-229.	2.4	10
262	Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation. <i>Annals of Hematology</i> , 2008, 87, 1023-1024.	1.8	9
263	Factor V HR2 haplotype: a risk factor for venous thromboembolism in individuals with absence of Factor V Leiden. <i>Annals of Hematology</i> , 2008, 87, 1013-1016.	1.8	14
264	Plasmapheresis in asparaginase-induced hypertriglyceridemia. <i>Transfusion</i> , 2008, 48, 1227-1230.	1.8	22
265	Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 265-270.	1.4	11
266	Anti colon cancer components from Lebanese sage (<i>Salvia libanotica</i>) essential oil: Mechanistic basis. <i>Cancer Biology and Therapy</i> , 2008, 7, 1765-1773.	3.7	74
267	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. <i>Blood</i> , 2008, 111, 3770-3777.	1.4	37
268	Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. <i>Haematologica</i> , 2008, 93, e36-e37.	3.5	31
269	WS1-2-4 Phase I Clinical Study of Anti-apoptosis Protein, Survivin-derived Peptide Vaccine Therapy for Patients with Advanced or Recurrent Urothelial Cancer(Urothelial Cell Cancer). <i>Japanese Journal of Urology</i> , 2008, 99, 146.	0.0	0
270	Zidovudine and interferon- β treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. <i>Leukemia and Lymphoma</i> , 2007, 48, 330-336.	1.4	38

#	ARTICLE	IF	CITATIONS
271	An overview of the pathogenesis and natural history of post-transplant T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1237-1241.	1.4	5
272	An overview of the pathogenesis and natural history of post-transplant T-cell lymphoma (corrected) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> <i>Leukemia and Lymphoma</i> , 2007, 48, 1780-1784.	1.4	11
273	Xenogenic bone matrix extracts induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. <i>Regenerative Medicine</i> , 2007, 2, 383-390.	1.9	35
274	Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. <i>Haematologica</i> , 2007, 92, 753-762.	3.5	48
275	A Worldwide Meta-Analysis on the Use of Zidovudine and Interferon-alpha for the Treatment of Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2007, 110, 2049-2049.	1.4	12
276	Molecular Mechanisms of NF-kappaB Activation by the HTLV-I Oncoprotein Tax: Role of Post Translational Protein Modification.. <i>Blood</i> , 2007, 110, 4159-4159.	1.4	0
277	Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2007, 110, 1379-1379.	1.4	4
278	Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2006, 142, 1-9.	3.4	302
279	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. <i>Blood</i> , 2006, 108, 1021-1029.	1.4	131
280	Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF- κ B activation. <i>Blood</i> , 2006, 107, 4021-4029.	1.4	99
281	The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (<i>Saimiri sciureus</i>). <i>Antiviral Research</i> , 2006, 70, 132-139.	4.2	9
282	A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3585-3588.	0.8	12
283	Differences in Fetal Hemoglobin Induction in Sickle Cell Disease and beta-Thalassemia.. <i>Blood</i> , 2006, 108, 555-555.	1.4	2
284	Additive Effect of Butyrate and Hemin on Fetal Hemoglobin Induction in Erythroid Cells from Sickle Cell Disease and Beta-Thalassemia.. <i>Blood</i> , 2006, 108, 1224-1224.	1.4	0
285	Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamide. <i>Biochemical Journal</i> , 2005, 392, 231-239.	3.8	8
286	Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. <i>Oncogene</i> , 2005, 24, 419-430.	5.9	74
287	Tax Ubiquitylation and Sumoylation Control the Two Distinct Steps of NF- κ B Activation.. <i>Blood</i> , 2005, 106, 4353-4353.	1.4	0
288	Carbohydrate-carbohydrate interaction provides adhesion force and specificity for cellular recognition. <i>Journal of Cell Biology</i> , 2004, 165, 529-537.	5.2	130

#	ARTICLE	IF	CITATIONS
289	Ceramide Inhibits IL-2 Production by Preventing Protein Kinase C-Dependent NF- κ B Activation: Possible Role in Protein Kinase C β Regulation. <i>Journal of Immunology</i> , 2004, 173, 3193-3200.	0.8	36
290	Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. <i>The Hematology Journal</i> , 2004, 5, 130-134.	1.4	128
291	Desmogleins 1 and 3 in the Companion Layer Anchor Mouse Anagen Hair to the Follicle. <i>Journal of Investigative Dermatology</i> , 2004, 123, 817-822.	0.7	41
292	N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. <i>Leukemia</i> , 2004, 18, 607-615.	7.5	27
293	Hemophagocytic syndrome as a presenting sign of transformation of smoldering to acute adult T-cell leukemia/lymphoma: Efficacy of anti-retroviral and interferon therapy. <i>American Journal of Hematology</i> , 2004, 76, 187-189.	4.3	15
294	Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center. <i>Journal of Clinical Apheresis</i> , 2004, 19, 119-124.	1.2	14
295	New therapeutic approaches for adult T-cell leukaemia. <i>Lancet Oncology</i> , The, 2004, 5, 664-672.	10.8	120
296	A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. <i>Blood</i> , 2004, 103, 1838-1845.	1.4	105
297	Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1314-1323.	1.4	113
298	The Inhibitor of VEGF-Receptors Tyrosine Kinase PTK-787 Blocks the Invasive Potential of Adult T-Cell Leukemia Cells through the Endothelium.. <i>Blood</i> , 2004, 104, 84-84.	1.4	0
299	Mentor effects in the genus <i>Hieracium</i> S.STR. (Compositae, Lactuceae). <i>Folia Geobotanica</i> , 2003, 38, 345-350.	1.0	51
300	Loss of CD20 expression in relapsed lymphomas after rituximab therapy. <i>European Journal of Haematology</i> , 2003, 70, 330-332.	2.2	51
301	Signet ring-like light chain myeloma with systemic spread. <i>European Journal of Haematology</i> , 2003, 70, 249-250.	2.2	7
302	The Central Region of Human T-Cell Leukemia Virus Type 1 Tax Protein Contains Distinct Domains Involved in Subunit Dimerization. <i>Journal of Virology</i> , 2003, 77, 13028-13035.	3.5	34
303	Effective treatment of hypereosinophilic syndrome with imatinib mesylate. <i>The Hematology Journal</i> , 2003, 4, 410-412.	1.4	23
304	Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. <i>Blood</i> , 2003, 101, 4576-4582.	1.4	98
305	Glicemia p \bar{A} ³ s-prandial. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2003, 47, 728-738.	1.0	12
306	Serum Flt3 Ligand Variation as a Predictive Indicator of Hematopoietic Stem Cell Mobilization. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 533-538.	1.9	15

#	ARTICLE	IF	CITATIONS
307	Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. <i>Blood</i> , 2002, 99, 3383-3389.	1.4	66
308	Human T-cell lymphotropic virus oncoprotein Tax represses TGF- β 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. <i>Blood</i> , 2002, 100, 4129-4138.	1.4	91
309	Acute viral hepatitis A and parvovirus B19 infections complicated by pure red cell aplasia and autoimmune hemolytic anemia. <i>Journal of Hepatology</i> , 2002, 37, 163-165.	3.9	25
310	A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. <i>The Hematology Journal</i> , 2002, 3, 276-282.	1.4	109
311	Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. <i>Virus Research</i> , 2001, 78, 79-92.	2.3	64
312	Treatment-resistant infantile Evans syndrome. <i>Pediatrics International</i> , 2001, 43, 502-504.	0.5	5
313	Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural α -Galactosyl IgG antibodies. <i>Xenotransplantation</i> , 2001, 8, 15-23.	3.0	64
314	Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor β -positive human T-cell lymphotropic virus type-I-transformed cells. <i>The Hematology Journal</i> , 2001, 2, 127-135.	1.4	19
315	Role of commensal relationships on the spatial structure of a surface-attached microbial consortium. <i>Environmental Microbiology</i> , 2000, 2, 59-68.	3.9	185
316	Interferon alpha is an effective therapy for congenital dyserythropoietic anaemia type I. <i>European Journal of Haematology</i> , 2000, 65, 207-209.	2.2	16
317	Arsenic Trioxide and Interferon- β Synergize to Induce Cell Cycle Arrest and Apoptosis in Human T-Cell Lymphotropic Virus Type 1-Transformed Cells. <i>Blood</i> , 1999, 93, 278-283.	1.4	174
318	Arsenic Trioxide and Interferon- β Synergize to Induce Cell Cycle Arrest and Apoptosis in Human T-Cell Lymphotropic Virus Type 1-Transformed Cells. <i>Blood</i> , 1999, 93, 278-283.	1.4	10
319	Esophageal Intramural Metastasis from an Adenocarcinoma of the Gastric Cardia: Report of a Case. <i>Surgery Today</i> , 1998, 28, 1160-1162.	1.5	10
320	Thiamine-responsive myelodysplasia. <i>British Journal of Haematology</i> , 1998, 102, 1098-1100.	2.7	50
321	Adult T Cell Leukaemia. <i>BioDrugs</i> , 1998, 10, 447-462.	5.0	38
322	Optimal stopping and maximal inequalities for geometric Brownian motion. <i>Journal of Applied Probability</i> , 1998, 35, 856-872.	0.8	17
323	Agent-supported information retrieval for tracking and tracing. <i>Lecture Notes in Computer Science</i> , 1998, , 44-54.	1.0	0
324	Treatment with a Combination of Zidovudine and β -Interferon in Naive and Pretreated Adult T-Cell Leukemia/Lymphoma Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, S186-S190.	0.4	61

#	ARTICLE	IF	CITATIONS
325	Human T-cell leukemia virus type I (HTLV-I) and transplantation. , 1996, , 81-87.		0
326	Human T-cell-leukemia virus type I in post-transfusional spastic paraparesis: Complete proviral sequence from uncultured blood cells. International Journal of Cancer, 1995, 63, 494-499.	5.4	31
327	Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa. New England Journal of Medicine, 1995, 332, 1749-1751.	30.1	262
328	Cytoskeletal regulation of chemotactic receptors: Molecular complexation of Nâ€formyl peptide receptors with G proteins and actin. European Journal of Haematology, 1993, 51, 288-293.	2.2	55
329	Effect of Kondo Resonance Scattering on Magnetoacoustic Quantum Oscillations. Europhysics Letters, 1987, 4, 1177-1181.	2.0	5
330	Changes in processing and labelling of frozen chicken products available to consumers in Vancouver. BCIT Environmental Public Health Journal, 0, , .	0.0	0
331	Work in Progress: Understanding how Action ModesÂ® can Help or Hinder Students in Self-paced Courses. , 0, , .		0
332	Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia, 0, , .	7.5	0
333	Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia, 0, , .	7.5	0
334	Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT. Bone Marrow Transplantation, 0, , .	2.4	0
335	Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<scp>WBMT</scp>). American Journal of Hematology, 0, , .	4.3	0
336	An international survey to better understand the current incidence, severity, and management of VOD/SOS. Bone Marrow Transplantation, 0, , .	2.4	0
337	Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation. Bone Marrow Transplantation, 0, , .	2.4	0